# Enmai Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enmai-biotechnology

- Industry: Pharmaceuticals
- Headquarters: Guangzhou, China
- Latest round: Series A (Feb 24, 2026)
- Investors on record: 2

## About

Based in Guangzhou, China, and founded in 2021, Guangzhou Enmai Biotechnology Co., Ltd., trading as Enmai Biotechnology, is an innovative drug developer that develops innovative clinical diagnostic reagents and antibody drugs based on antibody technology, focusing on the integrated precision diagnosis and treatment of sepsis, viral infections, and autoimmune diseases. In February 2026, Enmai Biotechnology raised a series A funding from Xietong Investment and JC Capital.
The company focuses on the research and development of innovative and precision diagnostic technologies for infectious and chronic inflammatory diseases. Its main products include precision diagnostic kits for sepsis, antibody drugs, and innovative diagnostic and treatment solutions.
The company’s revenue is generated by providing drugs for infectious and chronic diseases.

## Funding rounds

- Series A, Feb 24, 2026 — JC Capital, Syn Capital

## Investors

- JC Capital (https://capitalatlas.ai/funds/jc-capital) — Series A
- Syn Capital — Series A